you are invited to join the study and asked to read and sign a consent form after the study procedures are explained in plain language.

initial measurements are taken, including a lung function test called forced vital capacity (fvc) that measures how much air you can exhale.

your medical history and current health status are recorded.

you are randomly assigned to receive either the active drug pipe-791 or a matching placebo tablet.

the tablets are identical in appearance, and you will not know which one you receive.

you begin taking the study tablet by mouth.

each tablet contains 000 mg of the assigned substance.

the exact schedule for taking the tablet (for example, once daily) is provided by the study staff and must be followed for the duration of the trial.

throughout the study you are asked to report any new symptoms or side effects, referred to as treatment emergent adverse events (teae).

regular phone calls or visits may be arranged to check your well‑being.

you return to the clinic approximately 12 weeks after starting the medication.

the same lung function test (fvc) is repeated and any side effects are reviewed.

approximately 26 weeks after starting the medication you attend the final study visit.

a final fvc measurement is performed, the study medication is stopped, and all study data are collected.

the overall effectiveness and safety of the treatment are evaluated at this time.

after the week 26 visit you complete any remaining paperwork and receive information about the overall study results when they become available.